137.75

6.70% 8.65

Axsome Therapeutics Inc (AXSM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AXSM Giù? Forum Previsione

Precedente Chiudi:

$129.10

Aprire:

$130.04

Volume 24 ore:

1.48M

Relative Volume:

1.74

Capitalizzazione di mercato:

$6.54B

Reddito:

$338.46M

Utile/perdita netta:

$-310.96M

Rapporto P/E:

-21.09

EPS:

-6.53

Flusso di cassa netto:

$-132.82M

1 W Prestazione:

+5.03%

1M Prestazione:

+43.22%

6M Prestazione:

+56.69%

1 anno Prestazione:

+67.76%

Intervallo 1D:

$128.38

$139.13

Intervallo di 1 settimana:

$124.03

$139.13

Portata 52W:

$64.11

$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Nome

Axsome Therapeutics Inc

Settore

Healthcare (1169)

Industria

Biotechnology (678)

Telefono

(212) 332-3241

Indirizzo

ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK

Dipendente

569

Cinguettio

Prossima data di guadagno

2025-02-18

Ultimi documenti SEC

AXSM's Discussions on Twitter

Confronta AXSM con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AXSM Axsome Therapeutics Inc	137.75	6.54B	338.46M	-310.96M	-132.82M	-6.53
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-12-31	Reiterato	Mizuho	Outperform
2024-09-03	Iniziato	Wells Fargo	Overweight
2024-08-06	Aggiornamento	BofA Securities	Neutral → Buy
2024-07-22	Iniziato	Needham	Buy
2024-04-29	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-06	Iniziato	UBS	Buy
2024-01-25	Iniziato	RBC Capital Mkts	Outperform
2023-12-13	Iniziato	Citigroup	Buy
2023-08-08	Aggiornamento	BofA Securities	Underperform → Neutral
2023-01-05	Iniziato	Piper Sandler	Neutral
2022-11-01	Iniziato	Loop Capital	Buy
2022-09-07	Ripresa	Mizuho	Buy
2021-08-10	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-06-10	Iniziato	Berenberg	Buy
2021-01-08	Iniziato	Jefferies	Buy
2020-12-16	Iniziato	Mizuho	Buy
2020-09-29	Iniziato	BofA Securities	Underperform
2020-09-10	Iniziato	Morgan Stanley	Overweight
2020-04-28	Reiterato	H.C. Wainwright	Buy
2020-04-14	Iniziato	Cowen	Outperform
2019-12-30	Reiterato	H.C. Wainwright	Buy
2019-12-17	Reiterato	H.C. Wainwright	Buy
2019-12-16	Reiterato	Guggenheim	Buy
2019-10-16	Iniziato	Guggenheim	Buy
2019-09-18	Iniziato	William Blair	Outperform
2019-05-28	Iniziato	SunTrust	Buy
2019-05-23	Reiterato	H.C. Wainwright	Buy
2019-04-08	Iniziato	SVB Leerink	Outperform
2019-03-15	Reiterato	H.C. Wainwright	Buy
2016-10-03	Ripresa	Brean Capital	Buy
2015-12-15	Iniziato	Cantor Fitzgerald	Buy
2015-12-14	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

11:42 AM

Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat

11:42 AM

09:10 AM

Axsome Therapeutics stock soars to all-time high of $134.2 By Investing.com - Investing.com Nigeria

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Axsome Therapeutics stock soars to all-time high of $134.2 - Investing.com India

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Astrazeneca, Vertex, Axsome secure US FDA approvals in January - BioWorld Online

Feb 21, 2025

Axsome Therapeutics targets multiple NDA submissions and pipeline advancements through 2025 - MSN

Feb 21, 2025

Mizuho maintains Axsome Outperform rating, $195 target - Investing.com

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $200.00 at HC Wainwright - MarketBeat

Feb 21, 2025

FY2028 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat

Feb 21, 2025

Axsome Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks

Feb 21, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Peregrine Capital Management LLC - MarketBeat

Feb 21, 2025

Strategic Financial Concepts LLC Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Feb 21, 2025

Feb 20, 2025

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - AOL

Feb 20, 2025

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN

Feb 20, 2025

Axsome Therapeutics (NASDAQ:AXSM) Receives Outperform Rating from William Blair - MarketBeat

Feb 20, 2025

Truist Financial Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Cantor Fitzgerald Reaffirms Overweight Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat

Feb 20, 2025

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering (NASDAQ:AXSM) - Seeking Alpha

Feb 20, 2025

Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Axsome Therapeutics Revenue Surges 66% - MSN

Feb 20, 2025